Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16414766 | 1.00 | GPR119 (0.47) | GPR119MMP13PRMT5WDR77KMT2A | |
| SCHEMBL15600231 | 0.94 | GPR119 (0.53) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL16415382 | 0.91 | KMT2A (0.44) | GPR119MMP13PRMT5WDR77KMT2A | |
| SCHEMBL30869937 | 0.91 | GPR119 (0.50) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL21458369 | 0.91 | GPR119 (0.50) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL21458869 | 0.91 | GPR119 (0.50) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL30804273 | 0.91 | GPR119 (0.50) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL30750650 | 0.87 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL29547933 | 0.87 | GPR119 (0.48) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL30750659 | 0.86 | GPR119 (0.53) | GPR119MMP13KMT2AMEN1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015011252-A1 | PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031674-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | GPR119 2426/4885MMP13 3502/4885PRMT5 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.